Arbutus Biopharma (NASDAQ:ABUS) was upgraded by stock analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued on Wednesday.
A number of other equities research analysts have also recently commented on the company. Zacks Investment Research upgraded Arbutus Biopharma from a “sell” rating to a “hold” rating in a research note on Thursday, March 22nd. Chardan Capital initiated coverage on Arbutus Biopharma in a research note on Monday, March 19th. They set a “buy” rating and a $8.25 target price on the stock. ValuEngine upgraded Arbutus Biopharma from a “sell” rating to a “hold” rating in a research note on Thursday, March 15th. Finally, Wedbush cut Arbutus Biopharma from an “outperform” rating to a “neutral” rating and lowered their target price for the stock from $9.00 to $6.00 in a research note on Monday, March 19th. Three analysts have rated the stock with a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $12.33.
Arbutus Biopharma opened at $6.40 on Wednesday, according to MarketBeat Ratings. Arbutus Biopharma has a one year low of $6.45 and a one year high of $6.60. The company has a quick ratio of 16.86, a current ratio of 16.86 and a debt-to-equity ratio of 0.01.
A number of institutional investors and hedge funds have recently made changes to their positions in ABUS. Spark Investment Management LLC increased its holdings in Arbutus Biopharma by 98.3% in the 4th quarter. Spark Investment Management LLC now owns 23,000 shares of the biopharmaceutical company’s stock worth $116,000 after acquiring an additional 11,400 shares during the last quarter. Citadel Advisors LLC purchased a new stake in Arbutus Biopharma in the 4th quarter worth about $146,000. DekaBank Deutsche Girozentrale purchased a new stake in Arbutus Biopharma in the 1st quarter worth about $174,000. Two Sigma Investments LP purchased a new stake in Arbutus Biopharma in the 4th quarter worth about $215,000. Finally, Goldman Sachs Group Inc. purchased a new stake in Arbutus Biopharma in the 4th quarter worth about $275,000. 62.16% of the stock is owned by institutional investors.
About Arbutus Biopharma
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi).
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.